← Back to Search

Unknown

QLS-101 for Ocular Hypertension

Phase 2
Waitlist Available
Research Sponsored by Qlaris Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 100 days
Awards & highlights

Summary

This trial is testing a new eye drop (QLS-101) against an existing one (timolol maleate) in patients with high eye pressure due to glaucoma or ocular hypertension. The goal is to determine if the new treatment is safe and effective in lowering eye pressure. Timolol maleate has been used for almost two decades to treat glaucoma and ocular hypertension, showing significant efficacy in reducing eye pressure.

Eligible Conditions
  • Ocular Hypertension
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~100 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 100 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ocular safety
Secondary study objectives
Ocular hypotensive efficacy

Side effects data

From 2015 Phase 4 trial • 157 Patients • NCT02003391
6%
Ocular hyperaemia
5%
Eye pruritus
2%
Nasopharyngitis
2%
Dry eye
1%
Eye irritation
1%
Blepharal pigmentation
1%
Cataract
1%
Conjunctivitis allergic
1%
Acute tonsillitis
1%
Eyelids pruritus
1%
Pharyngitis
1%
Arthritis
1%
Hypersensitivity
1%
Eye pain
1%
Ocular surface disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
DuoTrav
Beta-blocker

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: QLS-101 2%Experimental Treatment1 Intervention
Group II: QLS-101 1%Experimental Treatment1 Intervention
Group III: QLS-101 0.5%Experimental Treatment1 Intervention
Group IV: Timolol Maleate 0.5% preservative free ophthalmic solutionActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QLS-101
2021
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

Qlaris Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
203 Total Patients Enrolled
4 Trials studying Ocular Hypertension
113 Patients Enrolled for Ocular Hypertension
~19 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top